FDA Issues Voluntary Recall on Reumofan Plus Tablets
Feb. 20, 2013
The U.S. Food and Drug Administration (FDA) and drug manufacturer Reumofan Plus USA, LLC & Reumofan USA, LLC have announced the voluntary recall of the companies’ medication, Reumofan Plus. According to a press release from the agency, the drug contains undeclared active ingredients that can result in a serious or life threatening Drug Injury.
The medication was marketed online, and was sold in packages of 30 tablets to treat conditions such as:
– Muscle pain.
– Bone cancer.
Testing of the medication discovered that the drug may contain active ingredients not included on the product’s label, including methocarbamol, dexamethasone, and diclofenac. This can result in a patient who should not ingest these compounds taking the drug. The defect has already led to at least one person seeking medical attention after suffering a drug injury from the medication.
Anyone currently taking the drug has been instructed to its halt use immediately and to discuss further use of Reumofan Plus with a physician. They should then return the product to the manufacturer for an herbal replacement. The FDA also reminds anyone who has suffered an adverse effect from the medication to report the incident.
The Colorado Personal Injury Lawyers at McDivitt Law Firm suggest discussing your legal rights and options with a qualified attorney as soon as possible if you have been been harmed while taking a medication.Back to the Blog